26th Mar 2018 09:31
The collaboration will evaluate a potential enzyme replacement therapy using NanoMedSyn's proprietary synthetic derivatives named AMFA.
"NanoMedSyn has demonstrated innovation in advancing the next generation of enzyme replacement therapy, and Shire is pleased to enter this research agreement with NanoMedSyn," said Andreas Busch, head of research & development and chief scientific officer at Shire.
"The novel design of AMFA and the promising biological activity demonstrated in preclinical models makes this program an exciting opportunity for Shire to further expand its commitment to evaluating potential advancements in lysosomal storage disorder treatments," Busch added.
Lysosomal storage disorders are inherited metabolic disorders that are characterized by an abnormal build-up of various toxic materials in the body's cells as a result of enzyme deficiencies.
The AMFA compound is designed for the targeting of a specific membrane lectin, the mannose 6-phosphate receptor, a major intracellular lysosomal trafficking pathway. Preclinical data demonstrate that AMFA has a high affinity for binding to the M6P receptor.
Under the terms of the agreement, the companies will perform preclinical evaluations of AMFA conjugated to recombinant enzyme. Shire will provide funding to NanoMedsyn under the agreement. Further terms of the agreement were not disclosed.
Shares in Shire were up 1.2% at
Related Shares:
Shire